Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alex J Pfeil"'
Autor:
Michael F Coleman, Kristina K Camp, Tori L McFarlane, Steven S Doerstling, Subreen A Khatib, Erika T Rezeli, Alfor G Lewis, Alex J Pfeil, Laura A Smith, Laura W Bowers, Farnaz Fouladi, Weida Gong, Elaine M Glenny, Joel S Parker, Ginger L Milne, Ian M Carroll, Anthony A Fodor, Randy J Seeley, Stephen D Hursting
Obesity promotes triple-negative breast cancer (TNBC), and effective interventions are urgently needed to break the obesity-TNBC link. Epidemiologic studies indicate that bariatric surgery reduces TNBC risk, while evidence is limited or conflicted fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8accbd6ca33dc60a91ca287911fc2a4
https://doi.org/10.1101/2023.05.19.541484
https://doi.org/10.1101/2023.05.19.541484
Autor:
Suhas K. Etigunta, Michael F. Coleman, Kristyn A. Liu, Alex J. Pfeil, Zhengrong Cui, Stephen D. Hursting
Publikováno v:
Cancer Research. 82:3507-3507
Background: Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. PDAC often presents at advanced tumor stages, resulting in poor survival rates. Immunotherapies such as inhibition of programmed death 1 (PD1) are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c497768996319fc8b2ce64cc47bd8bbf
https://doi.org/10.1158/1538-7445.am2022-3507
https://doi.org/10.1158/1538-7445.am2022-3507
Autor:
Laura M. Lashinger, Stephen D. Hursting, Suhas K. Etigunta, Alex J. Pfeil, Zhengrong Cui, Michael F. Coleman
Publikováno v:
Cancer Research. 81:1565-1565
Background: Pancreatic ductal adenocarcinoma (PDAC) has a five year survival rate in single digits.This is driven by a number of factors including limited effective therapeutic options for the management of PDAC. Immunotherapies such as inhibition of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b39b4b48fe1d33a9f54affaa055d8835
https://doi.org/10.1158/1538-7445.am2021-1565
https://doi.org/10.1158/1538-7445.am2021-1565
Autor:
Suhas K. Etigunta, Alex J. Pfeil, Laura M. Lashinger, Kristyn A. Liu, Stephen D. Hursting, Salvador Fabela, Michael F. Coleman, Zhengrong Cui, Xiaohu Tang
Publikováno v:
Cancer Research. 81:3151-3151
Background: Pancreatic ductal adenocarcinoma (PDAC) remains the 4th most deadly cancer in the US. Current chemotherapeutic regimens poorly control PDAC progression and no approved immunotherapeutic options currently exist. PDAC incidence and progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d10455ebee0b575af917b09ff50f3e5b
https://doi.org/10.1158/1538-7445.am2021-3151
https://doi.org/10.1158/1538-7445.am2021-3151